Navigation Links
Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
Date:4/1/2008

European Medicines Agency (EMEA) Grants Orphan Drug Status for the

Treatment of Spina Bifida

EAST NORRITON, Pa., April 1 /PRNewswire/ -- Tengion Inc. announced today that the European Medicines Agency (EMEA) and the European Commission (EC) have formally designated Tengion's autologous urothelial and smooth muscle cells -- the Neo-Bladder Augment(TM) -- as an Orphan Medicinal Product for the treatment of spina bifida.

This Orphan Medicinal Product Designation qualifies Tengion and its Neo- Bladder Augment for EMEA regulatory incentives, including eligibility for protocol assistance and possible exemptions or reductions of certain regulatory fees. Orphan Product designation also enables the Neo-Bladder Augment to qualify for 10 years of marketing exclusivity in the EU upon marketing approval.

In accordance with directives set forth by the European Commission, EMEA's Committee for Orphan Medicinal Products (COMP) agreed that Tengion's Autologous Neo-Bladder Construct meets the criteria for being designated as an EU Orphan Medicinal Product, for the treatment of spina bifida. Spina bifida is a debilitating illness that frequently results in neurogenic bladder. Although satisfactory methods of treatment for the neurogenic bladder have been authorized by EMEA, justifications have been provided that the Neo- Bladder Augment may be of significant clinical benefit to those patients with spina bifida who suffer from neurogenic bladder and warrant surgical intervention for their condition.

"We are extremely pleased that EMEA and the European Commission has recognized the Neo-Bladder Augment's potential to significantly improve the treatment of neurogenic bladder in spina bifida patients -- a critically underserved patient population," said Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "We look forward to continuing to work with the EMEA, as we are with the U.S. Food and Drug Administration, to determine the most effective and efficient regulatory path forward for our neo-organs and neo-tissues."

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create a functional neo- organ or neo-tissue that is designed to harness an individual's ability to regenerate specific organ tissue, catalyzing the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.


'/>"/>
SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Appoints Jeff Randall to Board of Directors
2. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
3. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
4. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
5. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
6. Human Pheromone Sciences Announces Quarterly and Full Year Results
7. Dragon Pharma announces 2007 full year financial results
8. Genaera Corporation Announces 2007 Financial Results
9. Genmab Announces Year End 2007 Financial Results
10. Immunosyn Corporation Announces 2007 Results, Files 10KSB
11. Elbit Imaging Ltd. Announces Results For Fiscal Year 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... ... treasurer for the Mid-Atlantic chapter of the Healthcare Businesswomen’s Association (HBA). ... The HBA Mid-Atlantic chapter board meets in person once each quarter and holds ...
(Date:5/24/2017)... ... May 23, 2017 , ... Federal funding for basic and applied scientific research ... medical and other vital technologies — deserves continued support, say leaders of SPIE, ... community today in responding to the President’s budget request for Fiscal Year 2018. , ...
(Date:5/23/2017)... Toronto, Canada (PRWEB) , ... May 23, 2017 ... ... of Firmex FileSend, a cloud-based file transfer solution that makes it easy for ... firewall without having to worry about cumbersome FTP software or email file size ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a leading ... marking the occasion with a strong presence at Bio-IT World Conference & Expo ... extends an invitation to all attendees to view posters on the entire ...
Breaking Biology Technology:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):